Drug intelligence / Profile preview

FoTv

Development stage: Unknown
Lead developer: Gordon Saxe
Modality: Small Molecules
Administration: Oral

Overview

FoTv is an investigational natural product supplement consisting of a 50/50 blend of mycelium from two medicinal fungi: *Fomitopsis officinalis* (agarikon) and *Trametes versicolor* (turkey tail). Developed by Gordon Saxe at UC San Diego in collaboration with Fungi Perfecti, LLC, it is being evaluated for its immunomodulatory and antiviral properties in the treatment of COVID-19. The supplement is administered orally in capsule form. It is hypothesized to enhance the immune response and potentially inhibit viral replication, though specific molecular targets are not fully characterized in the provided context. Clinical evaluation includes a Phase 1/2 trial for mild-to-moderate COVID-19 outpatients and studies as a vaccine adjunct.

Other names: Fomitopsis officinalis and Trametes versicolorAgarikon and Turkey Tail blend

Beyond the preview

Go deeper on FoTv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FoTv.

Explore the full profile